Percutaneous Nephroscopic Resection of Pyelocaliceal Transitional Cell Carcinoma in Solitary Kidney

Bo Yang

Shahekou District Zhongshan Road 467, Dalian, Liaoning, China

Abstract

Percutaneous approaches to upper tract urothelial cancers have been performed in patients unsuitable for radical nephroureterectomy. We present the case of a 72-year old man with a tumor involving the right renal pelvis and the middle and lower calyces in a solitary kidney which was successfully treated by percutaneous nephroscopic resection using monopolar electrocautery.

Keywords: Percutaneous nephroscopic resection; Renal pelvis; Transitional cell carcinoma

Introduction

Nephroureterectomy with the excision of the ipsilateral ureteral orifice and bladder cuff has been considered the standard treatment of the urinary upper transitional cell carcinoma. However, due to the morbidity associated with open nephroureterectomies, conservative management may be appropriate for poor surgical candidates, especially in those with impaired renal function or a solitary kidney.

With the development of equipment and techniques for percutaneous access, percutaneous nephroscopic surgery can be used for treating upper urinary tract urothelial malignancies.

We report the case of an upper tract urothelial carcinoma in the renal pelvis resected with monopolar electrocautery through percutaneous access.

Case Report

A 72-year-old male presented with intermittent right flank pain and microscopic hematuria for 4 weeks. His left kidney, ipsilateral ureter, and bladder cuff was removed due to left renal pelvic carcinoma before 7 years. A computed tomography of urinary tract (CTU) demonstrated an intraluminal filling defect, measuring 3×2cm, with hydrocalycosis in middle and lower calyces (Figure 1 and Figure 2). There was no evidence of metastases. Urine cytology was positive for urothelial carcinoma for three times, so retrograde ureteroscopy was not performed.

Based on a background of a solitary kidney, the options were discussed with the patient and a tumor resection with monopolar electrocautery through percutaneous access was carried out. With the patient under general anesthesia and in the prone position, the percutaneous nephrostomy puncture of the right kidney was performed under both C-arm fluoroscopic and ultrasonic guidance. The dilated middle calyces was chosen for puncture, and the tract was dilated to 30 F, then an Amplatz sheath was inserted. A 24 Fr resectoscope (R.Wolf resectoscope) using monopolar cautery was used to resect the tumor
A large number of cases published in the literature has confirmed the safety and efficacy of percutaneous treatment in selected patients with upper tract TCC of low grade and stage [3]. The advantages of the percutaneous approach are the use of larger instruments, better vision, complete resection of large tumors, deeper biopsies, and better staging [1,4]. Also, the percutaneous tract makes it easy to do a second look procedure and adjuvant topical therapy.

Complication rates with the percutaneous approach are low and include blood transfusion in <20% and less commonly, PUJ obstruction from stricture, adjacent organ injury, and pleural injury [5]. Potential disadvantages include the increased morbidity and the theoretical concern over tract seeding. However, percutaneous tract seeding is rare in patients with upper-tract TCC.

The holmium:YAG and neodymium:YAG lasers have been used successfully to cauterize and ablate upper tract urothelial tumours. But both ureteroscopy and percutaneous laser ablation would have been tedious due to tumor size and location. And although the safeness of the lasers has been proved, there still report of bleeding complication which subsequently developed an arteriovenous fistula [6]. So electrocautery was introduced in the ureteroscopic and percutaneous management. Electrocautery is traditionally used for transurethral resection of lower urinary tract lesions. When administered in endoscopic procedure the treatment technique is similar to bladder therapies with the caveat that the upper urinary tract is composed of thinner walled structures overlying large vascular structures. Endoscopic resection similar to TURBT should not be performed percutaneously in the intrarenal collecting system [7]. For practical purposes the cut and coagulation levels should be set as low as possible to obtain the desired tissue effect.

In a study Kevin G et al. [8] demonstrated that bipolar electrocautery is a safe and feasible resection modality in percutaneously approached upper tract urothelial neoplasms in patients with cardiac pacemakers. Moreover, bipolar electrocautery has been shown to reduce the depth of thermal damage at the site of surgery, hence prevent excessive heat from penetrating deeply into parenchyma and resulting in AV fistula. For reason of lack of the equipment, we used monopolar electrocautery for resection. In our experience, with a setting of lower watts and cautious manipulation, monopolar electrocautery is as safe as bipolar electrocautery. And with a big percutaneous channel and cutting loop, the resection was more efficient and cost saving.

Percutaneous approaches show recurrence rates and disease-specific survival in the patients with low grade tumors (Grades 1-2) of 26% to 28% and 96% to 100%, respectively [1]. Rouprêt M et al. [9] compared patients undergoing nephroureterectomy versus ureteroscopic and percutaneous management for upper urinary tract transitional cell carcinoma and noted no statistically significant differences in 5-year disease-specific survival rate for either treatment group (84%, 80.7%, and 80%, respectively).

Typically, a second look procedure is performed within several days of the initial procedure. Any remaining tumor is treated. Intracavitary adjuvant therapy (BCG or mitomycin) can be administered 2 weeks after the resection, assuming a nephrostogram is normal [10].

The aim of instilling chemo- or immunotherapeutic agents post resection is to reduce tumor recurrence. Agents can be administered via a percutaneous nephrostomy after percutaneous management, or via
an ureteric catheter following ureteroscopic treatment. Essentially, the same agents have been used to treat the upper tract as have been used in the bladder, namely mitomycin C, thiotepa and Bacillus Calmette-Guérin (BCG). If adjuvant BCG is given, it is recommended that to avoid systemic absorption and possible sepsis, instillation of agents to the upper tract should be performed under low pressure (25 cm water) and in the absence of infection [11].

In one case report, the patient received intravesical BCG by keeping the double-J stent in place to permit reflux of the agent into the renal pelvis [6]. But some authors suggest that placing agents in the bladder and hoping they will reflux up an internal double pigtail stent is more wishful than practical [7]. And a recently published large series of treating 133 renal units over a 20-year period demonstrated no benefit in reducing recurrence or progression with adjuvant BCG following percutaneous resection of upper tract TCC [12].

Conclusion

Endoscopic management was once considered a therapy of last resort, reserved for those with a solitary kidney, renal insufficiency, or severe medical co-morbidities.

Percutaneous treatment of upper tract urothelial tumors provides a reasonable alternative to nephroureterectomy in select patients. And electrocautery is a safe and feasible resection modality in percutaneously approached upper tract urothelial neoplasms in patients. As a palliative procedure, long-term surveillance is required for progression can occur postoperatively.

References

1. Soderdahl DW, Fabrizio MD, Rahman NU, Jarrett TW, Bagley DH (2005) Endoscopic treatment of upper tract transitional cell carcinoma. Urol Oncol 23: 114-122.
2. Box GN, Lehman DS, Landman J, Clayman RV (2008) Minimally invasive management of upper tract malignancies: renal cell and transitional cell carcinoma. Urol Clin North Am 35: 365-383.
3. Montanari E, Del Nero A, Bernardini P, Mangiarotti B, Confalonieri S, et al. (2005) Percutaneous therapy of low stage and grade urothelial neoplasia: long-term follow up. Arch Ital Urol Androl 77: 211-214.
4. Jabbour ME, Smith AD (2000) Primary percutaneous approach to upper urinary tract transitional cell carcinoma. Urol Clin North Am 27: 739-750.
5. Argyropoulos AN, Tolley DA (2007) Upper urinary tract transitional cell carcinoma: current treatment overview of minimally invasive approaches. BJU Int 99: 982-987.
6. Weber B, McCallum TJ, Tulip J, Moore RB (2008) Laser photoablation of renal pelvic tumours. Can Urol Assoc J 2: 413-416.
7. Grasso M (2008) Endoscopic management of upper urinary tract urothelial malignancies: broadening experience. Arch Esp Urol 61: 1070-1079.
8. Kwan KG, Chew BH, Luke PP, Denstedt JD, Pautler SE (2006) Percutaneous Resection of Renal Urothelial Carcinoma Using Bipolar Electrocautery. JSLS 10: 535-537.
9. Rouprêt M, Hupertan V, Traxer O, Loison G, Chartier-Kastler E, et al. (2006) Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology 67: 1181-1187.
10. Tae-Kon Hwang (2010) Percutaneous Nephrosurgical Surgery. Korean J Urol 51: 298-307.
11. Sagalowsky AI, Jarrett TW (2007) Management of urothelial tumors of the renal pelvis and ureter. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 9th ed. Philadelphia, PA: W.B. Saunders; pp. 1653–1685.
12. Rastinehad AR, Ost MC, Vanderbrink BA, Greenberg KL, El-Hakim A, et al. (2009) A 20-year experience with percutaneous resection of upper tract transitional carcinoma: Is there an oncologic benefit with adjuvant bacillus Calmette Guérin therapy? Urology 73: 27–31.